Pan CX - Search Results

1

Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy.

Zimmermann M, Li T, Semrad TJ, Wu CY, Yu A, Cimino G, Malfatti M, Haack K, Turteltaub KW, Pan CX, Cho M, Kim EJ, Henderson PT. Zimmermann M, et al. Among authors: pan cx. Mol Cancer Ther. 2020 Apr;19(4):1070-1079. doi: 10.1158/1535-7163.MCT-19-0133. Epub 2020 Feb 6. Mol Cancer Ther. 2020. PMID: 32029633 Free PMC article.

2

Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach.

Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Zhang H, et al. Among authors: pan cx. Urol Oncol. 2012 Sep;30(5):635-45. doi: 10.1016/j.urolonc.2010.06.011. Epub 2010 Oct 2. Urol Oncol. 2012. PMID: 20888272 Free PMC article.

3

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN Jr, Turteltaub K, Henderson P, Pan CX. Wang S, et al. Among authors: pan cx. Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. doi: 10.1021/tx1003547. Epub 2010 Oct 28. Chem Res Toxicol. 2010. PMID: 21028869 Free PMC article.

4

Human microdosing for the prediction of patient response.

Henderson PT, Pan CX. Henderson PT, et al. Among authors: pan cx. Bioanalysis. 2010 Mar;2(3):373-6. doi: 10.4155/bio.10.3. Bioanalysis. 2010. PMID: 21083245 Free PMC article. No abstract available.

5

Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.

Wang S, Zhang H, Cheng L, Evans C, Pan CX. Wang S, et al. Among authors: pan cx. Anticancer Res. 2010 Nov;30(11):4573-8. Anticancer Res. 2010. PMID: 21115908 Free PMC article.

6

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. Henderson PT, et al. Among authors: pan cx. Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4. Int J Cancer. 2011. PMID: 21128223 Free PMC article.

7

Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand.

Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO Jr, de Vere White R, Pan CX. Lin TY, et al. Among authors: pan cx. Mol Cancer. 2011 Jan 27;10(1):9. doi: 10.1186/1476-4598-10-9. Mol Cancer. 2011. PMID: 21272294 Free PMC article.

8

Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.

Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN Jr. Semrad TJ, et al. Among authors: pan cx. Invest New Drugs. 2012 Oct;30(5):2001-7. doi: 10.1007/s10637-011-9761-y. Epub 2011 Oct 21. Invest New Drugs. 2012. PMID: 22015991 Free PMC article. Clinical Trial.

9

Current treatment of metastatic bladder cancer and future directions.

Lei AQ, Cheng L, Pan CX. Lei AQ, et al. Among authors: pan cx. Expert Rev Anticancer Ther. 2011 Dec;11(12):1851-62. doi: 10.1586/era.11.181. Expert Rev Anticancer Ther. 2011. PMID: 22117153 Review.

10

Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.

Zhang H, Luo J, Li Y, Henderson PT, Wang Y, Wachsmann-Hogiu S, Zhao W, Lam KS, Pan CX. Zhang H, et al. Among authors: pan cx. Nanomedicine. 2012 Oct;8(7):1116-24. doi: 10.1016/j.nano.2011.12.004. Epub 2011 Dec 23. Nanomedicine. 2012. PMID: 22197725 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

270 results

Search Page